CLOSEOUT LETTER
Furst-McNess Company MARCS-CMS 668925 —
- Delivery Method:
- VIA EMAIL NO HARD COPY TO FOLLOW
- Product:
- Animal & Veterinary
- Recipient:
-
Recipient NameMark Poeschl
-
Recipient TitleCEO
- Furst-McNess Company
1252 Bell Valley Road, Suite 220
Rockford, IL 61108
United States-
- jeff.davidson@mcness.com
- Issuing Office:
- Division of Human and Animal Food Operations West I
United States
United States
Dear Mark Poeschl,
The United States Food and Drug Administration has completed evaluation of your facility’s corrective actions in response to our Warning Letter CMS 668925, dated March 12, 2024. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your facility from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your facility to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
CDR Kelli Wilkinson
Branch Director, Office of Surveillance and Compliance
Center for Veterinary Medicine
U.S. Food and Drug Administration